Argenx is a biotechnology company focused on developing innovative therapies for the treatment of severe autoimmune diseases and cancer
The company utilizes its proprietary platform to discover and create monoclonal antibodies that target specific proteins in the immune system to modulate its response. By exploring a diverse pipeline of clinical-stage candidates, Argenx aims to address unmet medical needs and improve patient outcomes through its cutting-edge approaches in immunology and therapeutic development.
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows positive Phase 3 study results and could position nipocalimab as a key competitor against existing gMG treatments like UCB's Rystiggo and Argenx's Vyvgart.
